HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sharkey, R. M. Articles by Goldenberg, D. M. Search for Related Content PubMed PubMed Citation Articles by Sharkey, R. M. Articles by Goldenberg, D. M.

A Phase I Trial Combining High-Dose ⁹⁰Y-Labeled Humanized Anti-CEA Monoclonal Antibody with Doxorubicin and Peripheral Blood Stem Cell Rescue in Advanced Medullary Thyroid Cancer

¹ Center for Molecular Medicine and Immunology, Garden State Cancer Center, Belleville, New Jersey
² St. Joseph’s Hospital and Medical Center, Paterson, New Jersey

This trial determined the pharmacokinetics, dosimetry, and dose-limiting toxicity of ⁹⁰Y-hMN-14 IgG (humanized anticarcinoembryonic antigen [CEA, or CEACAM5] monoclonal antibody; labetuzumab), combined with doxorubicin and peripheral blood stem cell (PBSC) support in advanced medullary thyroid cancer (MTC) patients. Methods: Fifteen patients received an infusion of ¹¹¹In-hMN-14 IgG. One to 2 wk later, 14 patients received ⁹⁰Y-hMN-14 IgG, starting at 740 MBq/m², followed 24 h later with a fixed intravenous bolus dose of doxorubicin (60 mg/m²). Preharvested PBSCs were reinfused when the ⁹⁰Y activity in the body was 111 MBq/m². Results: The mean red marrow dose estimated for the ⁹⁰Y-hMN-14 IgG was 1.65 ± 0.59 mGy/MBq (n = 11), with normal organs ranging from 2.3 to 4.4 mGy/MBq. Eighty percent of all known lesions (125/156), including 78 of 79 bone and 16 putatively occult lesions, were targeted. The average radiation dose to the tumor was 15.1 ± 10.8 mGy/MBq (55.8 ± 39.8 cGy/mCi) ⁹⁰Y-hMN-4 IgG (n = 29 tumors in 8 patients), with a majority of the lesions receiving >2,000 cGy at an administered dose of 1,480 MBq/m². The average tumor-to-red marrow, tumor-to-liver, tumor-to-lungs, and tumor-to-kidneys ratios were 15.0 ± 11.0, 5.1 ± 3.6, 6.9 ± 6.1, and 9.0 ± 8.7, respectively. Cardiopulmonary toxicity was dose limiting at 1,850 MBq/m². Minor responses were noted in 2 patients and 1 patient had a partial response (68% reduction in local and hepatic metastatic disease). Conclusion: This treatment combination was well tolerated with complete recovery of blood counts and reversible nonhematologic toxicities at the maximum tolerated dose of 1,480 MBq/m². Evidence of antitumor response in these patients with advanced cancer was modest, but encouraging; this type of treatment may be more successful if applied to more limited, earlier-stage disease.

Key Words: carcinoembryonic antigen • medullary thyroid cancer • radioimmunotherapy • chemotherapy • dosimetry • monoclonal antibody

Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 8a-9a. [Full Text]  

This article has been cited by other articles:

				R. H. Wilson Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer Oncologist, October 1, 2006; 11(9): 1018 - 1024. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy J. Clin. Oncol., February 10, 2006; 24(5): 823 - 834. [Abstract] [Full Text] [PDF]

				J. Barbet, L. Campion, F. Kraeber-Bodere, J.-F. Chatal, and and the GTE Study Group Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6077 - 6084. [Abstract] [Full Text] [PDF]